A German Biotech's $6.5 Million Bet on the Next Heart Disease Breakthrough

Jan de Vries · 2026-08-28

The European biotech scene just got a major new player. Revier Therapeutics, launching from Heidelberg, Germany, has officially closed its Seed financing round, pulling in a significant $6.5 million. It's a strong signal of confidence in a new scientific approach aiming to tackle some of the most challenging heart conditions out there. Let's talk about what they're up against. Despite all the advances in medicine, millions of patients are still stuck with limited options. We're talking about conditions like heart failure with preserved ejection fraction (HFpEF) and atherosclerotic cardiovascular disease (ASCVD). They're complex, they're debilitating, and frankly, the current treatments often just don't cut it. That's the gap Revier is aiming to fill. They're not just tweaking existing drugs; they're going after the root of the problem. Their whole premise is that the next generation of medicines has to address the underlying biology driving these diseases. It's a more ambitious goal, sure, but it's also where the potential for real, long-term patient benefit lies. ### The Science Behind the Startup So, how do they plan to do it? The key is in a group of enzymes called histone deacetylases, or HDACs. These enzymes play a role in a bunch of severe diseases. The first generation of HDAC inhibitors had a big problem: they were like a blunt instrument, hitting multiple HDAC classes and causing nasty side effects that limited how much patients could tolerate. Revier's strategy is all about precision. They've developed the first therapeutic approach designed to selectively target just the class IIa HDACs. Think of it as a smart missile instead of a carpet bomb. Their small-molecule drugs are taken orally and are engineered to inhibit only the disease-causing activity, while leaving the healthy biological functions untouched. Prof. Johannes Backs, the company's scientific founder, puts it well. He says this precise mode of action is designed to be effective *and* maintain a much better safety profile. That's the holy grail in drug development – high efficacy without the punishing side effects. ### Why Investors Are Betting Big The $6.5 million seed round wasn't pulled together by accident. It was led by the KHAN Technology Transfer Fund II, with notable participation from High-Tech Gründerfonds (HTGF), VORNvc, and private investors through Revier Invest Heidelberg. This coalition of regional and specialist investors sees something special here. Michael Hamacher from KHAN summed up the investor excitement. He pointed to Revier's "differentiated class IIa HDAC strategy" as having the potential to finally unlock the therapeutic promise of HDAC biology, while avoiding the pitfalls of older approaches. Combine that with what he calls an "exceptional leadership team and deep scientific expertise," and you've got a company poised to potentially reshape the standard of care. ### What's Next for Revier Therapeutics? With the fresh capital in the bank, the focus now shifts to execution. The money is earmarked for some critical next steps: - Advancing their preclinical pipeline for cardiometabolic diseases. - Pushing their lead program for HFpEF forward. - Developing their second program targeting ASCVD. - Building out their operational, scientific, and clinical teams to scale up. It's a classic biotech journey – take groundbreaking science, secure smart funding, and run hard toward the clinic. The team, led by CEO Prof. Eva van Rooij, is driven by a mission to translate this complex HDAC inhibition science into tangible therapies. Their success could mean a new class of drugs that offer durable benefits for patients living with these chronic, life-altering conditions. For professionals watching the European startup and biotech landscape, Revier Therapeutics is a name to remember. They represent the kind of deep-science, high-potential venture that defines the next wave of medical innovation. The road from lab to patient is long and fraught with challenges, but with a clear strategy and strong backing, this Heidelberg startup is off to a powerful start.